US$ 29.06
glp-1 agonist pharmacology Mechanisms of Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation Mechanisms of action of GLP-1
Description
Telehealth Convenience: Complete process online without in-person doctor visits

Nausea was more frequent with tirzepatide vs placebo, especially with tirzepatide 15 mg (OR 5.60 [95% CI 3.12, 10.06]), associated with higher incidence of vomiting (OR 5.50 [95% CI 2.40, 12.59]) and diarrhoea (OR 3.31 [95% CI 1.40, 7.85])

Zenodo (2024)

19 A 2023 meta-analysis of six observational studies reported no DR risk associated with GLP-1 RA use

Craig, C
